Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 18/20 | 1.00 |
| ▸ | MAOA | P21397 | 8/20 | 0.57 |
| ▸ | MAOB | P27338 | 8/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239558 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOBEPHX2ALDH1A1 | |
| SCHEMBL2756020 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOBEPHX2ALDH1A1 | |
| SCHEMBL240926 | 0.82 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL2756021 | 0.82 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL240927 | 0.82 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL28426624 | 0.77 | KDM1A (0.62) | KDM1AMAOAMAOB | |
| SCHEMBL28426625 | 0.77 | KDM1A (0.62) | KDM1AMAOAMAOB | |
| SCHEMBL28896353 | 0.77 | KDM1A (0.62) | KDM1AMAOAMAOBALDH1A1 | |
| SCHEMBL28896354 | 0.77 | KDM1A (0.62) | KDM1AMAOAMAOBALDH1A1 | |
| SCHEMBL15806712 | 0.75 | CHRNA7 (0.70) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | claimed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2022-12-08 | — | — | US | disclosed |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2021-06-15 | — | — | US | disclosed |
| CN-111655247-A | Enhancing T cell function and treating T cell dysfunction disorders with a combination of a LSD inhibitor and a PD1 binding antagonist | 艾比克斯治疗私人有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20190085372-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2019-03-21 | — | — | US | disclosed |
| EP-3430015-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | Oryzon Genomics, S.A. (ES) | 2019-01-23 | — | — | EP | disclosed |
| US-20180284095-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS SA (ES) | 2018-10-04 | — | — | US | disclosed |
| EP-3307909-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | Oryzon Genomics, S.A. (ES) | 2018-04-18 | — | — | EP | disclosed |
| CN-107849611-A | biomarkers related to L SD1 inhibitors and uses thereof | 奥瑞泽恩基因组学股份有限公司 | 2018-03-27 | — | — | CN | disclosed |
| WO-2017158136-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS, S.A. (ES) | 2017-09-21 | — | — | WO | disclosed |
| WO-2016198649-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS, S.A. (ES) | 2016-12-15 | — | — | WO | disclosed |
| US-20160045456-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2016-02-18 | — | — | US | disclosed |
| US-8993808-B2 | Phenylcyclopropylamine derivatives and their medical use | ORYZON GENOMICS, S.A. (ES) | 2015-03-31 | — | — | US | disclosed |
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
| US-20180284095-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | KDM1B, EZH2, DOT1L | KDM1A 5/4885MAOA 526/4885MAOB 410/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
| US-20190085372-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | KDM1A 1515/4885MAOA 80/4885MAOB 143/4885 |
| US-20160045456-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | KDM1A 1515/4885MAOA 80/4885MAOB 143/4885 |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.